查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2102981

全球泛自閉症障礙患者人數分析與預測：2026-2035年

Global Autism Spectrum Disorder Patient Population Analysis and Forecast, 2026 - 2035
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

泛自閉症障礙是一種終身性的神經發展障礙，其特徵是持續存在的社交溝通障礙、興趣狹窄、重複性行為以及不同程度的支持需求。過去20年來，自閉症的盛行率穩定上升。這並非由單一原因造成，而是主要歸功於公眾意識的提高、診斷技術的進步以及發育評估服務的普及。近期全球估計數據顯示，2021年全球約有1/127的人患有自閉症，但盛行率在不同國家和地區之間存在顯著差異。

市場促進因素

人們對自閉症的認知不斷提高

擴大公眾意識宣傳活動、加強醫生培訓以及推廣以學校為基礎的發育篩檢項目，使得自閉症的診斷更加早，各年齡段確診病例數量也隨之增加。

診斷方法的改進

診斷指南的修訂、標準化評估工具的建立以及多學科評估中心的建立提高了診斷的準確性，並擴大了被診斷為自閉症的患者範圍。

擴大早期篩檢計劃

在幼兒時期進行定期發展篩檢，可以及早發現自閉症，使患者能夠更早接受介入服務，並改善長期發展結果。

擴大流行病學調查範圍

國家自閉症登記處、電子健康記錄和基於人口的監測計劃不斷加深我們對自閉症在全球的盛行率、發病率、人口分佈和醫療保健可近性的了解。

市場限制因素

發展中地區缺乏診斷技術

在許多中低收入國家，由於專家短缺、篩檢計畫不足和公眾意識薄弱，漏診仍然是一個問題。

診斷標準的區域差異

醫療基礎設施、調查方法和報告系統的差異導致各國估計值有顯著差異。

專家資源有限

一些地區發育小兒科、心理學家、神經科和行為專家的短缺，持續延遲診斷和全面的流行病學評估。

患者族群和流行病學發現

全球泛自閉症障礙患者可依診斷狀態、嚴重程度、年齡層、性別和地區進行分類。

按診斷狀態分類，患者群體包括已確診患者和未確診患者。雖然由於公眾意識的提高和篩檢的進步，確診病例數量持續成長，但仍有相當數量的個體未被確診，尤其是在醫療衛生系統低度開發的地區。

依病情嚴重程度分類，患者群體分為1級（需要支持）、2級（需要中度支持）和3級（需要大量支持）。各層級患者的分佈會影響他們獲得醫療保健服務的機會、教育支持需求以及長期照護計畫。

按年齡層別分類，患者群體包括兒童、青少年和成人。由於自閉症通常在幼兒時期被發現，因此兒童佔新確診病例的大多數。然而，隨著人們對成人自閉症的認知不斷提高，老年人的診斷數量也在增加。

雖然流行病學研究一​​直報告稱，男性自閉症的盛行率高於女性，但人們對女性自閉症症狀的認知不斷提高，正在提高診斷準確性，並縮小先前存在的診斷差距。

患者數量趨勢

隨著診斷技術的進步，全球自閉症患者人數也在不斷變化。

主要趨勢如下：

  • 在全球範圍內，被診斷患有自閉症的人數正在增加。
  • 定期進行發展篩檢，以便早期診斷。
  • 成人自閉症的診斷數量正在增加。
  • 女性對自閉症的認知度正在提高。
  • 各國擴大自閉症監測系統。
  • 數位診斷技術的應用範圍擴大。
  • 開發中國家意識日益增強。

區域趨勢

由於北美擁有完善的篩檢項目、完善的監測系統、先進的醫療保健基礎設施以及廣泛的發育專家資源，因此北美是自閉症患者人數最多的地區之一。

在歐洲，由於標準化的診斷指南、國家衛生系統、合作流行病學研究以及各個年齡層對自閉症認知的提高，大量患者得以得到治療。

預計亞太地區確診病例數量成長最快，這主要得益於醫療基礎設施的改善、發育篩檢的擴大、意識提升以及對兒童醫療服務投入的增加。

在拉丁美洲、中東和非洲，透過醫生教育、擴大篩檢工作和加強公共衛生計劃，自閉症的診斷系統不斷改進，但漏診仍然是一項重大挑戰。

流行病學情勢

國家登記系統、電子健康記錄、學校健康計劃和基於人群的監測系統日益為自閉症的流行病學狀況提供了支持。數據品質的提高使得對盛行率、人口分佈和醫療資源利用的估計更加準確，從而為藥物研發、醫療規劃和政策制定提供支持。

前景

泛自閉症障礙人群分析的未來發展將受益於發育篩檢、早期診斷、人工智慧輔助評估的不斷改進以及標準化診斷標準的廣泛應用。公眾意識的提高和流行病學監測的加強有望改善對既往未確診患者的識別，同時促進個人化干預策略的製定和未來治療方案的創新。

結論

根據《全球泛自閉症障礙人口分析》，預計到2035年，自閉症確診人數將持續成長，這得益於公眾意識的提高、早期篩檢的開展、診斷技術的改進以及流行病學調查的加強。儘管在診斷和醫療保健服務獲取方面仍存在區域差異，但監測系統、發育評估和公共衛生舉措的持續進步有望加強患者識別，並為長期的全球醫療保健規劃提供支援。

本報告的主要益處

  • 對全球泛自閉症障礙患者人口進行全面評估。
  • 對盛行率、人口趨勢和疾病負擔進行詳細分析。
  • 評估診斷模式、嚴重程度分佈和區域流行病學情況。
  • 為醫療保健規劃、臨床研究和商業性機會評估提供支援的見解。
  • 這將成為製藥公司、生技公司、醫療保健提供者、研究人員、政策制定者和投資者的寶貴資訊來源。

公司對我們報告的使用

患者群體預測、流行病學評估、醫療資源規劃、臨床試驗規劃、商業性機會評估、打入市場策略、投資分析和長期策略決策。

調查範圍

  • 歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期為 2026 年至 2035 年。
  • 對全球泛自閉症障礙。
  • 評估盛行率、發生率、已確診和未確診患者人數、人口分佈、疾病負擔和流行病學趨勢。
  • 評估篩檢計畫、診斷實踐、醫療保健服務利用、區域疾病負擔以及未來患者數量的成長。
  • 對 1、2 和 3 級泛自閉症障礙進行分析，包括兒童和成人患者、性別分佈、已確診和未確診患者，以及 2035 年的未來流行病學趨勢。

目錄

第1章：執行摘要

第2章：泛自閉症障礙概述

  • 泛自閉症障礙簡介
  • 疾病的定義與分類
  • 疾病的病理生理學
  • 遺傳和環境風險因素
  • 臨床症狀
  • 疾病負擔
  • 診斷標準和評估
  • 患者病程和護理路徑

第3章：患者族群調查調查方法

  • 研究目標
  • 人口建模框架
  • 資料來源和前提條件
  • 流行病學評估調查方法
  • 預測性調查方法
  • 數據檢驗和三角測量
  • 限制和先決條件

第4章：全球泛自閉症障礙患者人口概況

  • 患者總數
  • 確診患者總數
  • 接受治療的患者總數
  • 患者總數
  • 診斷率分析
  • 治療率分析
  • 人口成長趨勢
  • 預測分析

第5章：依疾病類型對患者群體進行細分

  • 症狀性自閉症
  • 非症候群型自閉症

第6章：依疾病嚴重程度對患者群體進行細分

  • 一級自閉症譜系障礙
  • 2級自閉症譜系障礙
  • 3級自閉症譜系障礙

第7章：依年齡層別對患者族群進行細分

  • 兒童（0-12歲）
  • 青少年（13-17歲）
  • 成年人口（18歲以上）

第8章 依性別對患者群體進行分類

  • 男性人口
  • 女性人口

第9章：差距分析

  • 已確診族群與未確診族群的比較
  • 接受治療組與未接受治療組的比較
  • 診斷延遲評估
  • 早期診斷趨勢
  • 獲得醫療服務評估
  • 治療方面的區域差異
  • 未來診斷趨勢
  • 未來治療方法引入的發展趨勢

第10章 區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第11章：主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第12章：病患數量預測模型

  • 全球患者數量預測
  • 區域患者數量預測
  • 各國患者數量預測
  • 疾病嚴重程度預測模型
  • 疾病類型預測模型
  • 特定年齡預測模型
  • 性別特異預測模型
  • 已診斷的人口預測模型
  • 處理後的人口預測模型

第13章：公司簡介

  • Roche
  • Yamo Pharmaceuticals
  • Stalicla SA
  • Axial Therapeutics
  • SciSparc Ltd.
  • Oryzon Genomics SA
  • Curemark, LLC
  • Neurochlore SAS
  • Jazz Pharmaceuticals plc
  • Servier

第14章：來自關鍵意見領袖（KOL）的見解

  • 患者群體趨勢
  • 診斷趨勢與挑戰
  • 疾病認知趨勢
  • 影響未來人口成長的因素
  • 專家對泛自閉症障礙負擔的看法

第15章：調查方法

第16章附錄

簡介目錄
Product Code: KSI-008987

Autism Spectrum Disorder is a lifelong neurodevelopmental condition characterized by persistent challenges in social communication, restricted interests, repetitive behaviors, and varying levels of support needs. The prevalence of autism has increased steadily over the past two decades, largely because of enhanced awareness, improved diagnostic practices, and broader access to developmental assessments rather than a single identifiable cause. According to recent global estimates, approximately one in every 127 people worldwide was living with autism in 2021, although prevalence varies considerably between countries and regions.

Market Drivers

Increasing Autism Awareness

Growing public awareness campaigns, physician education, and school-based developmental screening programs are contributing to earlier diagnosis and increasing identification of autism across all age groups.

Improved Diagnostic Practices

Updated diagnostic guidelines, standardized assessment tools, and multidisciplinary evaluation centers are improving diagnostic accuracy and expanding the recognized patient population.

Expansion of Early Screening Programs

Routine developmental screening during early childhood is enabling earlier identification of autism, allowing patients to access intervention services at younger ages and improving long-term developmental outcomes.

Growing Epidemiological Research

National autism registries, electronic health records, and population-based surveillance programs continue improving understanding of autism prevalence, incidence, demographic distribution, and healthcare utilization worldwide.

Market Restraints

Underdiagnosis in Developing Regions

Many low- and middle-income countries continue to experience underdiagnosis because of limited specialist availability, inadequate screening programs, and lower public awareness.

Regional Variability in Diagnostic Criteria

Differences in healthcare infrastructure, diagnostic methodologies, and reporting systems contribute to substantial variation in prevalence estimates across countries.

Limited Access to Specialists

Shortages of developmental pediatricians, psychologists, neurologists, and behavioral specialists continue delaying diagnosis and comprehensive epidemiological assessment in several regions.

Patient Population and Epidemiology Insights

The global autism spectrum disorder patient population can be segmented by diagnosis status, severity level, age group, gender, and geography.

By diagnosis status, the patient population includes diagnosed patients and undiagnosed patients. Although diagnosed cases continue to increase because of improved awareness and screening, a significant number of individuals remain undiagnosed, particularly in developing healthcare systems.

By severity level, the population includes Level 1 (requiring support), Level 2 (requiring substantial support), and Level 3 (requiring very substantial support). The distribution of patients across severity levels influences healthcare utilization, educational support requirements, and long-term care planning.

By age group, the patient population comprises children, adolescents, and adults. Pediatric patients account for the largest proportion of newly diagnosed cases because autism is generally identified during early childhood, while increasing recognition of adult autism is expanding diagnosis among older populations.

By gender, epidemiological studies consistently report a higher prevalence among males than females, although growing recognition of autism presentations in females is improving diagnostic accuracy and narrowing historical diagnostic gaps.

Patient Population Trends

The global autism patient population continues to evolve as diagnosis improves.

Key trends include:

  • Increasing global diagnosed autism population.
  • Earlier diagnosis through routine developmental screening.
  • Greater identification of autism in adults.
  • Improved recognition of autism in females.
  • Expansion of national autism surveillance systems.
  • Growing use of digital diagnostic technologies.
  • Increasing awareness across developing countries.

Regional Insights

North America accounts for one of the largest diagnosed autism populations because of comprehensive screening programs, well-established surveillance systems, advanced healthcare infrastructure, and broad access to developmental specialists.

Europe maintains a substantial patient population through standardized diagnostic guidelines, national healthcare systems, collaborative epidemiological research, and increasing awareness of autism across all age groups.

Asia-Pacific is expected to experience the fastest growth in diagnosed patient populations owing to improving healthcare infrastructure, expanding developmental screening, increasing public awareness, and growing investment in pediatric healthcare services.

Latin America and the Middle East & Africa continue improving autism diagnosis through physician education, expanded screening initiatives, and stronger public health programs, although underdiagnosis remains an important challenge.

Epidemiological Landscape

The epidemiological landscape for autism is increasingly supported by national registries, electronic medical records, school health programs, and population-based surveillance systems. Improvements in data quality are providing more accurate estimates of prevalence, demographic distribution, and healthcare utilization, supporting pharmaceutical research, healthcare planning, and policy development.

Future Outlook

The future of autism spectrum disorder patient population analysis will be driven by continued improvements in developmental screening, earlier diagnosis, artificial intelligence-assisted assessment, and broader implementation of standardized diagnostic criteria. Increasing awareness and stronger epidemiological surveillance are expected to improve identification of previously undiagnosed individuals while supporting development of personalized intervention strategies and future therapeutic innovations.

Conclusion

The Global Autism Spectrum Disorder Patient Population Analysis indicates continued growth in the diagnosed autism population through 2035, supported by expanding awareness, earlier screening, improved diagnostic practices, and stronger epidemiological research. Although regional disparities in diagnosis and healthcare access remain, ongoing advances in surveillance systems, developmental assessment, and public health initiatives are expected to strengthen patient identification and support long-term healthcare planning worldwide.

Key Benefits of this Report

  • Comprehensive assessment of the global autism spectrum disorder patient population.
  • Detailed analysis of prevalence, demographic trends, and disease burden.
  • Evaluation of diagnosis patterns, severity distribution, and regional epidemiology.
  • Insights supporting healthcare planning, clinical research, and commercial opportunity assessment.
  • Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, policymakers, and investors.

What Businesses Use Our Reports For

Patient population forecasting, epidemiological assessment, healthcare resource planning, clinical trial planning, commercial opportunity evaluation, market access strategy, investment analysis, and long-term strategic decision-making.

Report Coverage

  • Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
  • Comprehensive analysis of the global autism spectrum disorder patient population by diagnosis status, severity level, age group, gender, and geography
  • Evaluation of prevalence, incidence, diagnosed and undiagnosed populations, demographic distribution, disease burden, and epidemiological trends
  • Assessment of screening programs, diagnostic practices, healthcare utilization, regional disease burden, and future patient population growth
  • Analysis of Level 1, Level 2, and Level 3 autism spectrum disorder, pediatric and adult populations, gender distribution, diagnosed and undiagnosed patients, and future epidemiological opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Report Scope and Objectives
  • 1.2 Key Findings
  • 1.3 Patient Population Overview
  • 1.4 Epidemiological Highlights
  • 1.5 Diagnosed Population Trends
  • 1.6 Regional Insights
  • 1.7 Key Growth Drivers
  • 1.8 Future Outlook (2025-2045)

2. Autism Spectrum Disorder Overview

  • 2.1 Introduction to Autism Spectrum Disorder
  • 2.2 Disease Definition and Classification
    • 2.2.1 Level 1 ASD (Requiring Support)
    • 2.2.2 Level 2 ASD (Requiring Substantial Support)
    • 2.2.3 Level 3 ASD (Requiring Very Substantial Support)
    • 2.2.4 Syndromic Autism
    • 2.2.5 Non-Syndromic Autism
  • 2.3 Disease Pathophysiology
  • 2.4 Genetic and Environmental Risk Factors
  • 2.5 Clinical Manifestations
  • 2.6 Disease Burden
  • 2.7 Diagnostic Criteria and Assessment
  • 2.8 Patient Journey and Care Pathway

3. Patient Population Methodology

  • 3.1 Study Objectives
  • 3.2 Population Modeling Framework
  • 3.3 Data Sources and Assumptions
  • 3.4 Epidemiological Assessment Methodology
  • 3.5 Forecasting Methodology (2025-2045)
  • 3.6 Data Validation and Triangulation
  • 3.7 Limitations and Assumptions

4. Global Autism Spectrum Disorder Patient Population Overview

  • 4.1 Total Patient Population
  • 4.2 Total Diagnosed Patient Population
  • 4.3 Total Treated Patient Population
  • 4.4 Total Eligible Patient Population
  • 4.5 Diagnosis Rate Analysis
  • 4.6 Treatment Rate Analysis
  • 4.7 Population Growth Trends
  • 4.8 Forecast Analysis (2025-2045)

5. Patient Population Segmentation by Disease Type

  • 5.1 Syndromic Autism
    • 5.1.1 Total Patient Population
    • 5.1.2 Diagnosed Population
    • 5.1.3 Treated Population
    • 5.1.4 Forecast Analysis
  • 5.2 Non-Syndromic Autism
    • 5.2.1 Total Patient Population
    • 5.2.2 Diagnosed Population
    • 5.2.3 Treated Population
    • 5.2.4 Forecast Analysis

6. Patient Population Segmentation by Disease Severity

  • 6.1 Level 1 ASD
    • 6.1.1 Total Patient Population
    • 6.1.2 Diagnosed Population
    • 6.1.3 Treated Population
    • 6.1.4 Forecast Analysis
  • 6.2 Level 2 ASD
    • 6.2.1 Total Patient Population
    • 6.2.2 Diagnosed Population
    • 6.2.3 Treated Population
    • 6.2.4 Forecast Analysis
  • 6.3 Level 3 ASD
    • 6.3.1 Total Patient Population
    • 6.3.2 Diagnosed Population
    • 6.3.3 Treated Population
    • 6.3.4 Forecast Analysis

7. Patient Population Segmentation by Age Group

  • 7.1 Pediatric Population (0-12 Years)
    • 7.1.1 Total Patient Population
    • 7.1.2 Diagnosed Population
    • 7.1.3 Treated Population
    • 7.1.4 Forecast Analysis
  • 7.2 Adolescent Population (13-17 Years)
    • 7.2.1 Total Patient Population
    • 7.2.2 Diagnosed Population
    • 7.2.3 Treated Population
    • 7.2.4 Forecast Analysis
  • 7.3 Adult Population (18 Years and Above)
    • 7.3.1 Total Patient Population
    • 7.3.2 Diagnosed Population
    • 7.3.3 Treated Population
    • 7.3.4 Forecast Analysis

8. Patient Population Segmentation by Gender

  • 8.1 Male Population
    • 8.1.1 Total Patient Population
    • 8.1.2 Diagnosed Population
    • 8.1.3 Treated Population
    • 8.1.4 Forecast Analysis
  • 8.2 Female Population
    • 8.2.1 Total Patient Population
    • 8.2.2 Diagnosed Population
    • 8.2.3 Treated Population
    • 8.2.4 Forecast Analysis

9. Diagnosis and Treatment Gap Analysis

  • 9.1 Diagnosed versus Undiagnosed Population
  • 9.2 Treated versus Untreated Population
  • 9.3 Delayed Diagnosis Assessment
  • 9.4 Early Diagnosis Trends
  • 9.5 Access to Care Assessment
  • 9.6 Regional Treatment Gaps
  • 9.7 Future Diagnosis Trends
  • 9.8 Future Treatment Adoption Trends

10. Geographical Analysis

  • 10.1 North America
    • 10.1.1 Total Patient Population
    • 10.1.2 Diagnosed Patient Population
    • 10.1.3 Treated Patient Population
    • 10.1.4 Disease Severity Distribution
    • 10.1.5 Age-Specific Population Analysis
    • 10.1.6 Gender-Specific Population Analysis
    • 10.1.7 Forecast Analysis
  • 10.2 Europe
    • 10.2.1 Total Patient Population
    • 10.2.2 Diagnosed Patient Population
    • 10.2.3 Treated Patient Population
    • 10.2.4 Disease Severity Distribution
    • 10.2.5 Age-Specific Population Analysis
    • 10.2.6 Gender-Specific Population Analysis
    • 10.2.7 Forecast Analysis
  • 10.3 Asia-Pacific
    • 10.3.1 Total Patient Population
    • 10.3.2 Diagnosed Patient Population
    • 10.3.3 Treated Patient Population
    • 10.3.4 Disease Severity Distribution
    • 10.3.5 Age-Specific Population Analysis
    • 10.3.6 Gender-Specific Population Analysis
    • 10.3.7 Forecast Analysis
  • 10.4 Latin America
    • 10.4.1 Total Patient Population
    • 10.4.2 Diagnosed Patient Population
    • 10.4.3 Treated Patient Population
    • 10.4.4 Disease Severity Distribution
    • 10.4.5 Age-Specific Population Analysis
    • 10.4.6 Gender-Specific Population Analysis
    • 10.4.7 Forecast Analysis
  • 10.5 Middle East & Africa
    • 10.5.1 Total Patient Population
    • 10.5.2 Diagnosed Patient Population
    • 10.5.3 Treated Patient Population
    • 10.5.4 Disease Severity Distribution
    • 10.5.5 Age-Specific Population Analysis
    • 10.5.6 Gender-Specific Population Analysis
    • 10.5.7 Forecast Analysis

11. Key Countries Analysis

  • 11.1 United States
    • 11.1.1 Total Patient Population
    • 11.1.2 Diagnosed Patient Population
    • 11.1.3 Treated Patient Population
    • 11.1.4 Disease Severity Distribution
    • 11.1.5 Age-Specific Population Analysis
    • 11.1.6 Gender-Specific Population Analysis
    • 11.1.7 Forecast Analysis
  • 11.2 Canada
    • 11.2.1 Total Patient Population
    • 11.2.2 Diagnosed Patient Population
    • 11.2.3 Treated Patient Population
    • 11.2.4 Disease Severity Distribution
    • 11.2.5 Age-Specific Population Analysis
    • 11.2.6 Gender-Specific Population Analysis
    • 11.2.7 Forecast Analysis
  • 11.3 Germany
    • 11.3.1 Total Patient Population
    • 11.3.2 Diagnosed Patient Population
    • 11.3.3 Treated Patient Population
    • 11.3.4 Disease Severity Distribution
    • 11.3.5 Age-Specific Population Analysis
    • 11.3.6 Gender-Specific Population Analysis
    • 11.3.7 Forecast Analysis
  • 11.4 United Kingdom
    • 11.4.1 Total Patient Population
    • 11.4.2 Diagnosed Patient Population
    • 11.4.3 Treated Patient Population
    • 11.4.4 Disease Severity Distribution
    • 11.4.5 Age-Specific Population Analysis
    • 11.4.6 Gender-Specific Population Analysis
    • 11.4.7 Forecast Analysis
  • 11.5 France
    • 11.5.1 Total Patient Population
    • 11.5.2 Diagnosed Patient Population
    • 11.5.3 Treated Patient Population
    • 11.5.4 Disease Severity Distribution
    • 11.5.5 Age-Specific Population Analysis
    • 11.5.6 Gender-Specific Population Analysis
    • 11.5.7 Forecast Analysis
  • 11.6 Italy
    • 11.6.1 Total Patient Population
    • 11.6.2 Diagnosed Patient Population
    • 11.6.3 Treated Patient Population
    • 11.6.4 Disease Severity Distribution
    • 11.6.5 Age-Specific Population Analysis
    • 11.6.6 Gender-Specific Population Analysis
    • 11.6.7 Forecast Analysis
  • 11.7 Spain
    • 11.7.1 Total Patient Population
    • 11.7.2 Diagnosed Patient Population
    • 11.7.3 Treated Patient Population
    • 11.7.4 Disease Severity Distribution
    • 11.7.5 Age-Specific Population Analysis
    • 11.7.6 Gender-Specific Population Analysis
    • 11.7.7 Forecast Analysis
  • 11.8 China
    • 11.8.1 Total Patient Population
    • 11.8.2 Diagnosed Patient Population
    • 11.8.3 Treated Patient Population
    • 11.8.4 Disease Severity Distribution
    • 11.8.5 Age-Specific Population Analysis
    • 11.8.6 Gender-Specific Population Analysis
    • 11.8.7 Forecast Analysis
  • 11.9 Japan
    • 11.9.1 Total Patient Population
    • 11.9.2 Diagnosed Patient Population
    • 11.9.3 Treated Patient Population
    • 11.9.4 Disease Severity Distribution
    • 11.9.5 Age-Specific Population Analysis
    • 11.9.6 Gender-Specific Population Analysis
    • 11.9.7 Forecast Analysis
  • 11.10 India
    • 11.10.1 Total Patient Population
    • 11.10.2 Diagnosed Patient Population
    • 11.10.3 Treated Patient Population
    • 11.10.4 Disease Severity Distribution
    • 11.10.5 Age-Specific Population Analysis
    • 11.10.6 Gender-Specific Population Analysis
    • 11.10.7 Forecast Analysis
  • 11.11 South Korea
    • 11.11.1 Total Patient Population
    • 11.11.2 Diagnosed Patient Population
    • 11.11.3 Treated Patient Population
    • 11.11.4 Disease Severity Distribution
    • 11.11.5 Age-Specific Population Analysis
    • 11.11.6 Gender-Specific Population Analysis
    • 11.11.7 Forecast Analysis
  • 11.12 Australia
    • 11.12.1 Total Patient Population
    • 11.12.2 Diagnosed Patient Population
    • 11.12.3 Treated Patient Population
    • 11.12.4 Disease Severity Distribution
    • 11.12.5 Age-Specific Population Analysis
    • 11.12.6 Gender-Specific Population Analysis
    • 11.12.7 Forecast Analysis

12. Patient Population Forecast Models

  • 12.1 Global Patient Population Forecast (2025-2045)
  • 12.2 Regional Patient Population Forecast
  • 12.3 Country-Level Patient Population Forecast
  • 12.4 Disease Severity Forecast Models
  • 12.5 Disease Type Forecast Models
  • 12.6 Age-Specific Forecast Models
  • 12.7 Gender-Specific Forecast Models
  • 12.8 Diagnosed Population Forecast Models
  • 12.9 Treated Population Forecast Models

13. Company Profiles

  • 13.1 Roche
    • 13.1.1 Overview
    • 13.1.2 Financials
    • 13.1.3 Autism Spectrum Disorder Portfolio Overview
    • 13.1.4 Patient Identification Strategy
    • 13.1.5 Target Patient Population Focus
    • 13.1.6 Clinical Development Programs
    • 13.1.7 Commercial Strategy
    • 13.1.8 Recent Developments
  • 13.2 Yamo Pharmaceuticals
    • 13.2.1 Overview
    • 13.2.2 Financials
    • 13.2.3 Autism Spectrum Disorder Portfolio Overview
    • 13.2.4 Patient Identification Strategy
    • 13.2.5 Target Patient Population Focus
    • 13.2.6 Clinical Development Programs
    • 13.2.7 Commercial Strategy
    • 13.2.8 Recent Developments
  • 13.3 Stalicla SA
    • 13.3.1 Overview
    • 13.3.2 Financials
    • 13.3.3 Autism Spectrum Disorder Portfolio Overview
    • 13.3.4 Precision Patient Stratification Strategy
    • 13.3.5 Target Patient Population Focus
    • 13.3.6 Clinical Development Programs
    • 13.3.7 Commercial Strategy
    • 13.3.8 Recent Developments
  • 13.4 Axial Therapeutics
    • 13.4.1 Overview
    • 13.4.2 Financials
    • 13.4.3 Autism Spectrum Disorder Portfolio Overview
    • 13.4.4 Patient Identification Strategy
    • 13.4.5 Target Patient Population Focus
    • 13.4.6 Clinical Development Programs
    • 13.4.7 Commercial Strategy
    • 13.4.8 Recent Developments
  • 13.5 SciSparc Ltd.
    • 13.5.1 Overview
    • 13.5.2 Financials
    • 13.5.3 Autism Spectrum Disorder Portfolio Overview
    • 13.5.4 Patient Identification Strategy
    • 13.5.5 Target Patient Population Focus
    • 13.5.6 Clinical Development Programs
    • 13.5.7 Commercial Strategy
    • 13.5.8 Recent Developments
  • 13.6 Oryzon Genomics S.A.
    • 13.6.1 Overview
    • 13.6.2 Financials
    • 13.6.3 Autism Spectrum Disorder Portfolio Overview
    • 13.6.4 Patient Identification Strategy
    • 13.6.5 Target Patient Population Focus
    • 13.6.6 Clinical Development Programs
    • 13.6.7 Commercial Strategy
    • 13.6.8 Recent Developments
  • 13.7 Curemark, LLC
    • 13.7.1 Overview
    • 13.7.2 Financials
    • 13.7.3 Autism Spectrum Disorder Portfolio Overview
    • 13.7.4 Patient Identification Strategy
    • 13.7.5 Target Patient Population Focus
    • 13.7.6 Clinical Development Programs
    • 13.7.7 Commercial Strategy
    • 13.7.8 Recent Developments
  • 13.8 Neurochlore SAS
    • 13.8.1 Overview
    • 13.8.2 Financials
    • 13.8.3 Autism Spectrum Disorder Portfolio Overview
    • 13.8.4 Patient Identification Strategy
    • 13.8.5 Target Patient Population Focus
    • 13.8.6 Clinical Development Programs
    • 13.8.7 Commercial Strategy
    • 13.8.8 Recent Developments
  • 13.9 Jazz Pharmaceuticals plc
    • 13.9.1 Overview
    • 13.9.2 Financials
    • 13.9.3 Autism Spectrum Disorder Portfolio Overview
    • 13.9.4 Patient Identification Strategy
    • 13.9.5 Target Patient Population Focus
    • 13.9.6 Clinical Development Programs
    • 13.9.7 Commercial Strategy
    • 13.9.8 Recent Developments
  • 13.10 Servier
    • 13.10.1 Overview
    • 13.10.2 Financials
    • 13.10.3 Autism Spectrum Disorder Portfolio Overview
    • 13.10.4 Patient Identification Strategy
    • 13.10.5 Target Patient Population Focus
    • 13.10.6 Clinical Development Programs
    • 13.10.7 Commercial Strategy
    • 13.10.8 Recent Developments

14. Key Opinion Leader (KOL) Insights

  • 14.1 Patient Population Trends
  • 14.2 Diagnostic Trends and Challenges
  • 14.3 Disease Awareness Trends
  • 14.4 Future Population Growth Drivers
  • 14.5 Expert Perspectives on ASD Burden

15. Research Methodology

  • 15.1 Primary Research
  • 15.2 Secondary Research
  • 15.3 Patient Population Modeling Methodology
  • 15.4 Forecasting Methodology
  • 15.5 Data Validation and Triangulation
  • 15.6 Assumptions and Limitations

16. Appendix

  • 16.1 Abbreviations
  • 16.2 Glossary of Terms
  • 16.3 References
  • 16.4 List of Tables
  • 16.5 List of Figures
  • 16.6 Epidemiology Databases
  • 16.7 Clinical Literature Sources
  • 16.8 Company Sources
  • 16.9 Healthcare Organization Sources